[1]杨文俊,胡成,刘思容,等.血清前列腺特异性抗原预测中国男性前列腺增生患者前列腺体积的准确性研究[J].中华腔镜泌尿外科杂志(电子版),2018,12(03):154-158.[doi:10.3877/cma.j.issn.1674-3253.2018.03.003 ]
 Yang Wenjun,Hu Cheng,Liu Sirong,et al.Accuracy of serum tPSA, fPSA in predicting prostate volume of Chinese LUTS/BPO-a single center study[J].,2018,12(03):154-158.[doi:10.3877/cma.j.issn.1674-3253.2018.03.003 ]
点击复制

血清前列腺特异性抗原预测中国男性前列腺增生患者前列腺体积的准确性研究()
分享到:

中华腔镜泌尿外科杂志(电子版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
12卷
期数:
2018年03期
页码:
154-158
栏目:
临床研究
出版日期:
2018-06-20

文章信息/Info

Title:
Accuracy of serum tPSA, fPSA in predicting prostate volume of Chinese LUTS/BPO-a single center study
作者:
杨文俊1胡成2刘思容1汤平1欧汝彪1韦兴华1谢克基1
510180 广州市第一人民医院泌尿外科1; 510630 广州,中山大学附属第三医院泌尿外科2
Author(s):
Yang Wenjun1 Hu Cheng2 Liu Sirong1 Tang Ping1 Ou Rubiao1 Wei Xinghua1 Xie Keji1.
1Department of Urology, Guangzhou First People's Hospital, Guangzhou 510180, China; 2Department of Urology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China
关键词:
前列腺特异性抗原下尿路症状前列腺增生前列腺体积
DOI:
10.3877/cma.j.issn.1674-3253.2018.03.003
摘要:
目的通过比较血清总前列腺特异性抗原(tPSA)、游离前列腺特异性抗原(fPSA)与年龄预测前列腺体积(PV)大小的准确性,寻找预测 PV简便易行、较准确的预测因子。方法收集 2005年 1月至 2014年 12月因下尿路症状到我院诊治下尿路症状 /良性前列腺梗阻(LUTS/BPO)患者的年龄、PV及 PSA检测值;采用 SPSS13.0软件处理数据,用皮尔森线性相关关系描述年龄、血清 tPSA及血清 fPSA与 PV的相关性,并采用卡方检验及受试者特征曲线(ROC)分析比较血清tPSA、血清 fPSA预测 PV的准确性。结果入选 6308例男性,皮尔森线性相关分析显示年龄-PV、tPSA-PV和 fPSA-PV的相关系数分别是0.197、0.434、和0.446,其 P值均<0.05,具有相关性;在 tPSA为0~4 μg/L时,tPSA和 fPSA预测 PV在(30~50)ml、(50~70)ml和 PV>70 ml组的 AUC-ROC分别为(0.617、0.732、0.761)和(0.625、0.738、0.767);在 tPSA为 0~4 μg/L时, tPSA和 fPSA预测 PV在(30~50) ml、(50~70)ml和 PV>70 ml组的最佳临界值分别为 tPSA(1.3 μg/L、 1.6 μg/L、2.0 μg/L)和 fPSA(0.3 μg/L、0.4 μg/L、0.5 μg/L)。结论中国 LUTS/BPO男性血清 fPSA与 PV正相关程度最高,血清 tPSA与 fPSA均可作为独立预测因子预测中国 LUTS/BPO男性的 PV,可作为临床上预测 PV简便易行的指标,其中 fPSA预测的准确性更高。

参考文献/References:

[1] 徐骏, 钱伟庆, 宋建达. 比较不同剂量舍尼通在防止良性前列腺增生疾病进程中的作用[J]. 中华男科学杂志, 2008, 14(6): 533-537.
[2] Filson CP, Hollingsworth JM, Clemens JQ, et al. The efficacy and safety of combined therapy with a-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis[J]. J Urol, 2013, 190(6): 2153-2160.
[3] Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia[J]. Eur Urol, 2003, 44(6): 695-700.
[4] Park DS, Oh JJ, Hong JY, et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study[J]. Asian J Androl, 2013, 15(2): 249-253.
[5] De Nunzio C, Autorino R, Bachmann A, et al. The diagnosis of benign prostatic obstruction: Development of a clinical nomogram[J]. Neurourol Urodyn, 2016, 35(2): 235-240.
[6] Coric J, Mujic J, Kucukalic E, et al. Prostate-specific antigen(PSA) and prostate volume:better predictor of prostate cancer for Bosnian and Herzegovina men[J]. Open Biochem J, 2015, 15(9): 34-36.
[7] Pejcic TP, Tulic CDz, Lalic NV, et al. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression[J]. Can J Urol, 2013, 20(2): 6707-6713.
[8] Schr?der FH, Hugosson J, Roobol MJ, et a1. Prostate cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012, 366(11): 981-990.
[9] Bohnen AM1, Groeneveld FP, Bosch JL. Serumprostate-specific antigen as a predictorof prostate volume in the community: the Krimpen study[J]. Eur Urol, 2007, 51(6): 1645-1652.
[10] Park DS1, Oh JJ, Hong JY , et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large scale Korean screening study[J]. Asian J Androl, 2013, 15(2): 249-253.
[11] Bansal A, Arora A. Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis[J]. Neurourol Urodyn, 2017, 36(7): 1757-1762.
[12] Yoshida T, Kinoshita H, Yoshida K , et al. Intravesical prostatic protrusion as a predicting factor for the adverse clinical outcome in patients with symptomatic benign prostatic enlargement treated with dutasteride[J]. Urology, 2016 ,91(1):154-157.
[13] Ho CC, Ngoo KS, Hamzaini AH, et al. Urinary bladder characteristics via ultrasound as predictors of acute urinary retention in men with benign prostatic hyperplasia[J]. Clin Ter, 2014, 165(2): 75-81.

相似文献/References:

[1]李辽源,高新,李解方,等.血清/尿PSA比值对血清PSA处于"灰区"中前列腺癌的诊断价值[J].中华腔镜泌尿外科杂志(电子版),2008,(03):52.
 LI Liao-yuan,GAO Xin,LI Xie-fang,et al.The role of the ratio of serum PSA and urine PSA in diagnosing prostate carcinoma within the serum PSA "gray" zone[J].,2008,(03):52.
[2]赵亮,王文卫,涂响安,等.经尿道双极等离子电切治疗前列腺增生122例临床分析[J].中华腔镜泌尿外科杂志(电子版),2011,(04):286.
 ZHAO Liang,WANG Wen-wei,TU Xiang-an,et al.Clinical analysis of transurethral bipolar plasma kinetic resection of the prostate for benign prostatic hyperplasia: Report of 122 cases[J].,2011,(03):286.

备注/Memo

备注/Memo:
基金项目:广州市医药卫生科技项目(20172A010002)
通讯作者:谢克基,Email: xiekeji@sina.com
更新日期/Last Update: 2018-06-20